Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Outcome Technologies (COTI), a developer of small molecules to treat cancer, has reported study results of its anti cancer drug candidate - COTI-2.
Subscribe to our email newsletter
COTI-2 uses the company’s proprietary artificial intelligence system – Chemsas which uses a series of predictive computer models to identify compounds integrated in disease-specific drug discovery.
COTI-2 inhibits the growth of cancer cells that over express Akt/Akt2.
The analysis of the new data confirms that tumor growth inhibition (TGI) was greater than 84% in all treatment groups and was associated with the dose of COTI-2.
There was an evidence that the increase in COTI-2 dose and TGI is associated with a decrease in total tumor Akt, Akt2 and Ser473_phosphoAkt, but not Thr308_phosphoAkt proteins.
The combined evidence indicates that a component of the COTI-2 effect is mediated through a decrease in both the amount and phospho-activation of the Akt2 component of total Akt protein.
COTI CEO Wayne Danter said they have established a relationship between the dose of COTI-2 and reduced levels of Akt/Akt2 protein, activated Akt/Akt2 in tumor tissues, and observed tumor growth inhibition.